Induction therapy in non small cell lung cancer: A comparison of clinical and post-surgical staging

P. L. Granone, S. Margaritora, A. Cesario, D. Galetta

Research output: Contribution to journalArticle

Abstract

In the last decade, several neoadjuvant trials for NSCLC. patients with mediastinal lymph node involvement (N2) have been scheduled. The uniform plan is based on clinical staging, therapy clinical re-staging, surgery (when is possible) and, finally, pathological staging The precise classification of tumor during the' three different staging procedures is mandatory. Considering clinical re-staging and pathological staqinq, nowadays surgery could be considered correct for most of the patients enrolled in the neoadjuvant protocols including cases where a major clinical response has not been achieved. Several experiences demonstrated how often the clinical re-staging overesteems neoplastic tissue by fibrosis and scar and could judge as unserectablc patients with a minimal residual disease.

Original languageEnglish
Pages (from-to)899-903
Number of pages5
JournalAnnali Italiani di Chirurgia
Volume70
Issue number6
Publication statusPublished - Nov 1999

Keywords

  • Lung cancer
  • N2 patients
  • Neoadjuvant therapy
  • Re-staging
  • Staging

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Induction therapy in non small cell lung cancer: A comparison of clinical and post-surgical staging'. Together they form a unique fingerprint.

  • Cite this